Full 1
Welcome to
GCC Oncology Updates Conference Series
Full 1
Full 2
Conference Series
Men's Health Edition
Full 2
Contact Us
CONFERENCE SERIES
Hematology Edition
Contact Us
previous arrow
next arrow

WELCOME

On behalf of the organizing committees, it gives us great pleasure to invite you to the GCC Oncology Updates, designed as a virtual event so all content will be available on the virtual platform.

Immerse yourself in the latest information in the oncology: Hematology Edition, Men’s Health Edition (Prostate & Urology), Women`s Health Edition (Breast & Gynecology), Internal Medicine Edition (Lung, Liver, Gastric & Colorectal).

The scientific program will also feature specialized Oncology Nursing Workshops.
New evidence-based approaches in diagnosis, treatment, clinical and translational research results, innovative techniques, diagnostic tools and risk-assessment strategies will be part of the program. You are Invited!

This is what the new and interactive #GCC-OU series has to offer:

  • Live program for each specialty
  • Parallel session halls with live and on-demand sessions
  • Plenary presentations, challenging cases & workshops
  • Satellite Symposia with updates in Oncology presented by pharmaceutical companies.
  • Live interactive panel discussions.
  • A virtual exhibition hosting top content from the industry partners.
  • All the scientific content to be available on-demand 30 days after each conference, for registered participants.
  • CME Accreditation recognized across all GCC

We look forward to your participation!

AGENDA

Friday

Neoplasms

}

1800 - 1805

Welcome Address & Introduction
}

1805 - 1825

New insights in the treatment of newly diagnosed multiple myeloma     
}

1825 - 1845

Chronic Lymphocytic Leukaemia in 2021: the Future Has Arrived
}

1845 - 1905

Management of relapsed/refractory multiple myeloma and minimal residual disease assessment
Meletios A. Dimopoulos
}

1905 - 1935

Satellite Symposium 
}

1935 - 1955

Chronic Lymphocytic Leukemia: update on diagnosis, risk stratification and treatment

Biosimilars

}

1955 - 2015

Emerging Role of Biosimilars in Oncology-Hematology in the GCC
}

2015 - 2035

The evolution of value with filgrastim in oncology
Abdullah Alsharm

Friday

Haematology Oncology Nursing Workshop

}

1800 - 1805

Welcome Address & Introduction
Khaled Al Qawasmeh
}

1805 - 1835

What do you to know? In Relapsed or Refractory Acute Lymphoblastic Leukemia Treatment options
Tahani Dweikat
}

1835 - 1905

Treatment of Acute Myeloid Leukemia   
Mahmoud Hasan
}

1905 - 1935

Treatment of relapsed or refractory diffuse large B-cell lymphoma
Khaled Al Qawasmeh
}

1935 - 2005

Management of Multiple myeloma
Mahmoud Hasan
}

2005 - 2035

GAZYVA in CLL and first-line FL
Khaled Al Qawasmeh
}

2035 - 2105

Immunotherapies: Management and Care for Patients with Hematology Malignancies
Tahani Dweikat
}

2105 - 2130

Nurses Open Forum Questions and discussion

Saturday

Lymphoma

}

1800 - 1805

Welcome Address & Introduction
}

1800 - 1820

Indolent and mantle-cell non-Hodgkin lymphoma – Clinical challenges 
Reyad Dada
}

1820 - 1840

Follicular lymphoma: 2021 update on diagnosis and management
John Allan
}

1840 - 1900

Hodgkin lymphoma – Clinical  Cases
Reyad Dada
}

1900 - 1920

Cellular, antibody and targeted therapy  
Ciprian Tomuleasa

2021 Updates On

}

1920 - 1940

Immunotherapy and other novel immunological therapies / Stem cell updates
}

1940 - 2000

International recommendations on the diagnosis and treatment of acquired haemophilia A   
}

2000 - 2030

Satellite Symposium 

Scientific Committee

Our Scientific Committee

Chairman 1

Chairman 1

Chairman

Chairman 2

Chairman 2

Chairman

Chairman 3

Chairman 3

Chairman

Speakers

Our Speakers

Meletios A. Dimopoulos

Meletios A. Dimopoulos

Khaled Al Qawasmeh

Khaled Al Qawasmeh

Tahani Dweikat

Tahani Dweikat

Mahmoud Hasan

Mahmoud Hasan

Reyad Dada

Reyad Dada

John Allan

John Allan

Ciprian Tomuleasa

Ciprian Tomuleasa

Partners and Supporting bodies:

EONS-logo

CME

Accreditation

THIS CONFERENCE WILL PROVIDE CONTINUING MEDICAL EDUCATION CREDIT POINTS CME credits, provided by Dubai Health Authority (DHA), will be announced 10 working days after the live conference days.

Certificates of Attendance will be emailed to the registered email address, under the registered full name, as a PDF within 10 days after the conclusion of the 30- days on demand, to allow maximum benefit to the participants. Attendance of 75% of the session is mandatory to claim your credit points. Attendance is monitored and recorded, for all live-days and the 30-days on-demand playback.